Rana McKay: CAPItello-281 phase 3 in PTEN-deficient Metastatic Hormone-Sensitive Prostate Cancer
Rana McKay, Associate Professor of Medicine at UC San Diego, shared a post on X:
“Exciting to see the long awaited outcome of the CAPItello-281 phase 3 in PTEN-deficient mHSPC demonstrating rPFS benefit with capivasertib + abiraterone.
Can’t wait to dig into the data.”
Dr. Rana McKay is a board-certified medical oncologist and specializes in urogenital cancers, offering treatment for bladder, kidney, prostate, and testicular cancer patients. Leading a multi-disciplinary prostate cancer clinic at UC San Diego, she ensures comprehensive care through collaboration with urologists and radiation oncologists. As an associate professor, Dr. McKay mentors students and conducts research on clinical trials and novel biomarkers for genitourinary malignancies. Dr. McKay is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.
For more Updates, Follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023